Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Leadership Transition: CEO Jean-Paul Clozel announced this was his last earnings call as CEO, with a new executive committee and board changes planned for a "new phase" at Idorsia.
TRYVIO Launch Plan: TRYVIO (aprocitentan) received FDA approval in March 2024 and is set for U.S. commercial availability in Q4 2024, with a full launch in Q1 2025 at a WAC price of $775 per month.
QUVIVIQ Performance: QUVIVIQ saw strong prescription volume in both the U.S. (~60,000 per quarter) and Europe, with payer-paid prescriptions in the U.S. rising to 73% by March 2024.
Revenue Dip Explained: U.S. QUVIVIQ net sales dipped in Q1 2024 due to patient insurance deductibles resetting, not a decline in demand.
Cost Savings & Cash: Cost-saving initiatives reduced both SG&A and R&D expenses; cash position improved to CHF 335 million at end of March 2024, boosted by the Viatris deal.
Strategic Deals: Closed major deals with Sosei Heptares (Nxera) and Viatris, including a $350 million upfront for two Phase III assets.
Guidance for 2024: Non-GAAP operating loss guidance is CHF 420 million, with net sales expected at CHF 55 million and R&D OpEx at CHF 165 million.
